No Way To Go But Grow: J&J Outlines Plans To Become A $60bn Pharma In 2025
Management outlined its growth strategy to investors, highlighting plans to file 14 novel drugs with more than $1bn in peak sales by 2025.
You may also be interested in...
The company admitted it may not meet a goal set in 2021 to reach a $60bn pharmaceutical revenue target in 2025.
The company's 2023 revenue guidance calls for 4.5%-5.5% growth, taking into account ongoing macroeconomic uncertainty and inflationary pressures.
Johnson & Johnson investors are turning attention to 2023, when the company's top-selling drug is set to face biosimilar competition in the US for the first time.